J O'Shaughnessy Selected Research

atezolizumab

1/2021

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J O'Shaughnessy Research Topics

Disease

28	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2000
8	Neoplasms (Cancer) 01/2021 - 12/2011
5	Triple Negative Breast Neoplasms 01/2022 - 08/2012
3	Disease Progression 01/2021 - 04/2015
2	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2018
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Cytopenia 01/2022
1	Retinoblastoma (Glioblastoma, Retinal) 01/2018
1	Alopecia (Baldness) 01/2017
1	Diarrhea 01/2017
1	Exanthema (Rash) 01/2017
1	Hyperglycemia 01/2017
1	Nausea 01/2017
1	Cardiotoxicity 10/2012
1	Hypertension (High Blood Pressure) 05/2012
1	Left Ventricular Dysfunction 05/2012
1	Proteinuria 05/2012
1	Neutropenia 06/2002
1	Hand-Foot Syndrome 02/2002
1	Enthesopathy 05/2001
1	Night Blindness (Nyctalopia) 01/2000

Drug/Important Bio-Agent (IBA)

7	Hormones (Hormone)IBA 01/2022 - 01/2018
5	Capecitabine (Xeloda)FDA Link 01/2021 - 02/2002
3	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 10/2012
3	abemaciclibIBA 01/2022 - 12/2021
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 01/2017
3	sacituzumab govitecanIBA 01/2021 - 12/2020
3	Letrozole (Femara)FDA LinkGeneric 11/2019 - 01/2016
3	ribociclibIBA 11/2019 - 01/2018
3	Trastuzumab (Herceptin)FDA Link 01/2019 - 12/2011
3	Bevacizumab (Avastin)FDA Link 01/2019 - 05/2012
3	Docetaxel (Taxotere)FDA Link 12/2013 - 09/2006
3	Tamoxifen FDA LinkGeneric 05/2001 - 01/2000
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2001
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 01/2017
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2021
2	taxaneIBA 01/2021 - 02/2002
2	Gemcitabine FDA Link 01/2021 - 01/2018
2	Lapatinib (GW572016)FDA Link 01/2019 - 12/2011
2	Anastrozole (Arimidex)FDA LinkGeneric 01/2018 - 01/2016
2	exemestane (Aromasin)FDA Link 01/2018 - 01/2016
2	Estrogen ReceptorsIBA 11/2017 - 01/2016
2	AnthracyclinesIBA 03/2012 - 02/2002
1	veliparibIBA 01/2022
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	Albumin-Bound Paclitaxel FDA Link 01/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021
1	B7-H1 AntigenIBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Topoisomerase InhibitorsIBA 01/2021
1	atezolizumabIBA 01/2021
1	eribulin FDA Link 01/2021
1	pembrolizumabIBA 01/2019
1	Cyclin D1IBA 01/2018
1	130-nm albumin-bound paclitaxelIBA 01/2018
1	palbociclibIBA 01/2018
1	Circulating Tumor DNAIBA 11/2017
1	NVP-BKM120IBA 01/2017
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2017
1	Aromatase InhibitorsIBA 01/2016
1	Abiraterone AcetateIBA 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Androgen Receptors (Androgen Receptor)IBA 01/2016
1	HematinicsIBA 04/2015
1	Biosimilar PharmaceuticalsIBA 04/2015
1	1-dodecylpyridoxal (PLD)IBA 10/2012
1	liposomal doxorubicin (Doxil)FDA Link 10/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2012
1	Monoclonal AntibodiesIBA 05/2012
1	human ERBB2 proteinIBA 12/2011
1	Taxoids (Taxanes)IBA 09/2006
1	pegfilgrastim (Neulasta)FDA Link 06/2002
1	Filgrastim (Neupogen)FDA Link 06/2002
1	HDL CholesterolIBA 05/2001
1	Alitretinoin FDA Link 05/2001
1	Vitamin A (Retinol)FDA LinkGeneric 01/2000
1	FenretinideIBA 01/2000
1	RetinoidsIBA 01/2000
1	retinamideIBA 01/2000

Therapy/Procedure

11	Therapeutics 01/2022 - 05/2001
10	Drug Therapy (Chemotherapy) 01/2021 - 01/2000
1	Neoadjuvant Therapy 01/2022
1	Adjuvant Chemotherapy 01/2021
1	Drug Tapering 02/2002